Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
| dc.contributor.author | Olazábal Morán, Manuel | |
| dc.contributor.author | Blázquez Barbadillo, Cristina | |
| dc.contributor.author | Pérez Izquierdo, Elena | |
| dc.contributor.author | Muñoz Silva, Miguel | |
| dc.contributor.author | Garrido Tarrío, Antonio | |
| dc.date.accessioned | 2026-03-10T16:09:06Z | |
| dc.date.available | 2026-03-10T16:09:06Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Reactive oxygen species (ROS) play a crucial role in maintaining cellular balance by acting both as signaling messengers and as sources of oxidative damage. In cancer, their role is paradoxical: moderate ROS levels can promote tumor growth and survival, whereas excessive ROS accumulation can trigger cell death. In lung cancer, the leading cause of cancer-related mortality worldwide, dysregulated ROS levels contribute to DNA instability, abnormal activation of signaling pathways, and resistance to therapy. This review integrates current insights into the dual functions of ROS in cancer, examines therapeutic strategies aimed at modulating ROS in lung cancer, and emphasizes the potential of ROS-activatable PROTACs as next-generation treatments for these patients. | en |
| dc.description.filiation | UEM | spa |
| dc.description.impact | 17.6 Q1 JCR 2024 | |
| dc.description.impact | 3.721 Q1 SJR 2024 | |
| dc.description.impact | No data IDR 2024 | |
| dc.description.sponsorship | Sin financiación | es |
| dc.identifier.citation | Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026). Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer. Advanced Drug Delivery Reviews, 233, 115840. https://doi.org/10.1016/j.addr.2026.115840 | |
| dc.identifier.doi | 10.1016/j.addr.2026.115840 | |
| dc.identifier.issn | 0169-409X | |
| dc.identifier.issn | 1872-8294 | |
| dc.identifier.uri | https://hdl.handle.net/11268/16944 | |
| dc.language.iso | eng | |
| dc.peerreviewed | Si | |
| dc.relation.publisherversion | https://doi.org/10.1016/j.addr.2026.115840 | |
| dc.rights.accessRights | embargoed access | |
| dc.subject.other | Neoplasias pulmonares | |
| dc.subject.other | Terapias en investigación | |
| dc.subject.other | Especies reactivas de oxígeno | |
| dc.subject.sdg | Goal 3: Ensure healthy lives and promote well-being for all at all ages | |
| dc.subject.unesco | Biología celular | |
| dc.subject.unesco | Cáncer | |
| dc.subject.unesco | Farmacología | |
| dc.title | Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer | |
| dc.type | journal article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 95df236f-9969-463b-a2b7-cbf1ac5d875b | |
| relation.isAuthorOfPublication | 10dac0b2-63a7-4be6-abed-32585380920e | |
| relation.isAuthorOfPublication.latestForDiscovery | 95df236f-9969-463b-a2b7-cbf1ac5d875b |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Harnessing reactive oxygen_2026
- Size:
- 11.68 MB
- Format:
- Adobe Portable Document Format

